Business Description
CytoDyn Inc
NAICS : 325412
SIC : 2834
ISIN : US23283M1018
Total Employee Number:
13Description
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.58 | |||||
Equity-to-Asset | -5.64 | |||||
Debt-to-Equity | -0.26 | |||||
Debt-to-EBITDA | -0.76 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year FCF Growth Rate | 60.7 | |||||
3-Year Book Growth Rate | 16.2 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 41.73 | |||||
9-Day RSI | 41.12 | |||||
14-Day RSI | 41.75 | |||||
3-1 Month Momentum % | 4.35 | |||||
12-1 Month Momentum % | 5.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.37 | |||||
Quick Ratio | 0.37 | |||||
Cash Ratio | 0.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20.2 | |||||
Shareholder Yield % | 0.45 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -241.99 | |||||
ROIC % | -95.99 | |||||
3-Year ROIIC % | -540.33 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -9.45 | |||||
EV-to-EBITDA | -9.46 | |||||
EV-to-Forward-Revenue | 24.84 | |||||
EV-to-FCF | -19.44 | |||||
Earnings Yield (Greenblatt) % | -10.58 | |||||
FCF Yield % | -5.49 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CytoDyn Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.026 | ||
| Beta | 1.4558 | ||
| 3-Year Sharpe Ratio | 0.38 | ||
| 3-Year Sortino Ratio | 0.77 | ||
| Volatility % | 64.74 | ||
| 14-Day RSI | 41.75 | ||
| 14-Day ATR (€) | 0.031035 | ||
| 20-Day SMA (€) | 0.2198 | ||
| 12-1 Month Momentum % | 5.26 | ||
| 52-Week Range (€) | 0.16 - 0.378 | ||
| Shares Outstanding (Mil) | 1,369.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CytoDyn Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CytoDyn Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-11-20 09:30 | In 140 days | ||
| First quarter earnings results for 2027 | 2026-10-09 | In 97 days | ||
| Annual report for 2026 | 2026-07-24 | In 20 days | ||
| Investor Webcast | 2026-04-30 13:00 | 0.25 (+0.80%) | ||
| Third quarter earnings results for 2026 | 2026-04-08 | 0.25 (+14.68%) | ||
| Second quarter earnings results for 2026 | 2026-01-09 | 0.23 (+13.86%) | ||
| General meeting for 2025 | 2025-11-21 09:30 | 0.29 (+18.85%) | ||
| LD Micro Main Event XIX | 2025-10-21 09:00 | 0.21 (+0.00%) | ||
| First quarter earnings results for 2026 | 2025-10-10 | 0.21 (+4.90%) | ||
| H.C. Wainwright 27th Annual Global Investment Conference | 2025-09-10 09:00 | 0.29 (+0.00%) |
Show
Entries
CytoDyn Inc Frequently Asked Questions
What is CytoDyn Inc(STU:296)'s stock price today?
The current price of STU:296 is €0.20. The 52 week high of STU:296 is €0.38 and 52 week low is €0.16.
When is next earnings date of CytoDyn Inc(STU:296)?
The next earnings date of CytoDyn Inc(STU:296) is 2026-10-09 Est..
Does CytoDyn Inc(STU:296) pay dividends? If so, how much?
CytoDyn Inc(STU:296) does not pay dividend.
Press Release
Articles on CytoDyn Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers